Senior Director, Bioanalytical and Biomarker Science and Technologies Takeda
New modalities call for a rapid advance in a diverse array of technologies that can better predict, characterize, and mitigate immunogenicity. With the increase in complexity of new modalities including: a reintroduction of foreign sequences which we had largely moved away from over the last 20 years, in vivo processing designed for tissue specific activation, and complex mechanisms of activation including immune cell engagement and stimulation, immunogenicity scientists are having to rethink their predictive, modeling, bioanalytical and clinical mitigation strategies. This talk will discuss some of the innovative technologies to advance complex portfolios and how we might better support both forward and reverse translation.
Learning Objectives:
Discuss various new technologies that can be employed for greater immunogenicity understanding.
Introduce members to novel strategies for interrogating immunogenicity.
Consider applications for forward and reverse translation.